Dyne Therapeutics, Inc. (DYN) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Waltham, MA, United States. El CEO actual es John G. Cox.
DYN tiene fecha de IPO 2020-09-17, 192 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $3.27B.
Dyne Therapeutics, Inc. is a biotechnology company focused on developing disease-modifying therapeutics for genetically driven muscle diseases. The company leverages its proprietary FORCE platform to advance treatment programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and other rare skeletal, cardiac, and metabolic muscle diseases. Founded in 2017 and headquartered in Waltham, Massachusetts, Dyne operates primarily in the United States market, addressing significant unmet medical needs in the muscle disease therapeutic space.
